Analysts expect Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN- Get a rating) will announce ($2.52) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Six analysts made estimates for Biohaven Pharmaceutical’s earnings, with the lowest EPS estimate being $3.59 and the highest estimate $0.65. Biohaven Pharmaceutical reported earnings per share of ($4.21) in the same quarter last year, suggesting a positive year-over-year growth rate of 40.1%. The company is due to release its next earnings report on Monday, January 1.
On average, analysts expect Biohaven Pharmaceutical to report annual earnings of $8.51 per share for the current fiscal year, with EPS estimates ranging from $10.23 to $6.85. For the next fiscal year, analysts expect the company to post earnings of ($3.79) per share, with EPS estimates ranging from ($6.83) to ($1.14). Zacks Investment Research EPS averages are an average based on a survey of sell-side research analysts who follow Biohaven Pharmaceutical.
Biohaven Pharmaceutical (NYSE: BHVN – Get a rating) last released its results on Friday, February 25. The company reported ($3.01) earnings per share for the quarter, missing analyst consensus estimates of ($2.07) by ($0.94). The company posted revenue of $190.01 million in the quarter, versus a consensus estimate of $175.54 million. Biohaven Pharmaceutical’s sales increased by 441.1% compared to the same quarter last year. During the same period last year, the company achieved EPS ($3.62).
Several stock analysts have recently released reports on the company. Morgan Stanley cut its price target on Biohaven Pharmaceutical from $148.00 to $146.00 and set an “equal weight” rating on the stock in a Wednesday, April 6 research note. Mizuho raised its target price on Biohaven Pharmaceutical from $144.00 to $154.00 and gave the stock a “buy” rating in a Thursday, March 3 report. Three equity research analysts gave the stock a hold rating and eight gave the stock a buy rating. According to data from MarketBeat, Biohaven Pharmaceutical currently has an average rating of “Buy” and an average price target of $148.27.
BHVN shares opened at $90.25 on Friday. Biohaven Pharmaceutical has a fifty-two week low of $65.24 and a fifty-two week high of $151.51. The stock has a 50-day moving average price of $112.37 and a two-hundred-day moving average price of $121.44. The company has a market capitalization of $6.37 billion, a P/E ratio of -6.90 and a beta of 1.20.
Institutional investors and hedge funds have recently changed their stakes in the company. Russell Investments Group Ltd. increased its position in Biohaven Pharmaceutical shares by 14.5% during the third quarter. Russell Investments Group Ltd. now owns 61,683 shares of the company worth $8,567,000 after purchasing an additional 7,791 shares last quarter. Two Sigma Advisers LP purchased a new stake in Biohaven Pharmaceutical stock during the third quarter valued at approximately $5,404,000. Balyasny Asset Management LLC purchased a new equity stake in Biohaven Pharmaceutical during the third quarter worth approximately $4,785,000. Teacher Retirement System of Texas increased its position in Biohaven Pharmaceutical shares by 40.3% during the third quarter. Teacher Retirement System of Texas now owns 9,254 shares of the company worth $1,285,000 after buying 2,660 additional shares last quarter. Finally, Profund Advisors LLC purchased a new equity stake in Biohaven Pharmaceutical during the third quarter at a value of approximately $1,531,000. Institutional investors and hedge funds hold 88.03% of the company’s shares.
Biohaven Pharmaceutical Company Profile (Get a rating)
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, is developing product candidates targeting neurological and neuropsychiatric diseases and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as the development of Rimegepant for the preventive treatment of migraine; Zavegepant which is in Phase III clinical trials for the acute and preventive treatment of migraine, as well as for respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications.
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Biohaven Pharmaceutical right now?
Before you consider Biohaven Pharmaceutical, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and Biohaven Pharmaceutical didn’t make the list.
Although Biohaven Pharmaceutical currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here